Using three different HER2‐tumour cell lines being more or less resistant to complement attack, we showed that mCRP and HER2 expression patterns (Fig. 6) further determine a second level of control on AP expansion and lytic MAC densities, controlling FHR4‐multimer‐mediated CDC efficacy (Fig. 5). The gene discussed is ERBB2; the disease is neoplasm.